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SETTING: Thyolo District Hospital, rural Malawi. 
OBJECTIVES: To report on 1) clinical, immunological 
and virological outcomes and 2) safety among human 
immunodefi  ciency virus (HIV) infected patients with 
tuberculosis (TB) who received concurrent nevirapine 
(NVP) and rifampicin (RMP) based treatment. 
DESIGN:  Retrospective cohort study.
METHODS:  Analysis of programme data, June–December 
2007. 
RESULTS: Of a total of 156 HIV-infected TB patients 
who started NVP-based antiretroviral treatment, 136 
(87%) completed TB treatment successfully, 16 (10%) 
died and 5 (4%) were transferred out. Mean body 
weight and CD4 gain (adults) were respectively 4.4 kg 
(95%CI 3.3–5.4) and 140 cells/mm3 (95%CI 117–162). 
Seventy-four per cent of patients who completed TB 
treatment and had a viral load performed (n = 74) had 
undetectable levels (<50 copies/ml), while 17 (22%) had 
a viral load of 50–1000 copies/ml. Hepatotoxicity was 
present in 2 (1.3%) patients at baseline. Two patients 
developed Grade 2 and one developed Grade 3 alanine 
transaminase enzyme elevations during TB treatment 
(incidence rate per 10 years of follow-up 4.2, 95%CI 
1.4–13.1). There were no reported deaths linked to 
hepatotoxicity. 
CONCLUSIONS:  In a rural district in Malawi, concomi-
tant NVP and RMP treatment is associated with good 
TB treatment outcomes and appears safe. Further follow-
up of patients would be useful to ascertain the longer-
term effects of this concurrent treatment. 
KEY WORDS: Malawi; HIV; tuberculosis; nevirapine; 
rifampicin; alanine transferase
IN MALAWI, a small resource-limited country in 
sub-Saharan Africa, 77% of newly registered tuber-
culosis (TB) patients are also infected by human im-
munodefi  ciency virus type 1 (HIV-1).1 Mortality dur-
ing the course of anti-tuberculosis treatment in such 
patients (case fatality) is high, and attributed to HIV-
related opportunistic infections.2 It is believed that 
antiretroviral treatment (ART) offered to HIV-positive 
TB patients reduces mortality and improves overall 
survival.
Malawi currently uses a fi  xed-dose combination 
of stavudine (d4T), lamivudine (3TC) and nevirapine 
(NVP) as its fi  rst-line ART regimen,3 and rifampicin 
(RMP) based drugs for the treatment of TB.4 RMP is 
a potent inducer of the liver enzyme cytochrome CYP 
450, responsible for the metabolism of non-nucleoside 
reverse transcriptase inhibitors (NNRTI) such as NVP 
and efavirenz (EFV). Plasma concentrations of NVP 
and EFV may thus be reduced when used concomi-
tantly with RMP, and this in turn may lead to sub-
optimal drug (NVP or EFV) exposure, treatment 
failure and emerging drug resistance.5 Increasing the 
dose of NVP or EFV to compensate for this interac-
tion increases the potential risk of toxicity and is thus 
not advised in recent World Health Organization 
(WHO) guidelines.6
Although EFV is considered the fi  rst choice for use 
in ART regimens along with RMP-based TB treat-
ment, the Ministry of Health of Malawi opted to use 
its standardised fi   rst-line ART regimen (containing 
NVP) also for co-infected TB patients, and this is what 
is recommended as the national protocol.3 This deci-
sion was made on the basis that 1) EFV is teratogenic, 
and nationally more than half of all HIV-infected TB 
patients are women of child-bearing age; with evident 
gaps in access to effective contraception at health 
centre level in Malawi, there is a real risk that moth-
ers can become pregnant during anti-tuberculosis 
treatment and ART; 2) EFV is not available in a ge-
neric fi  xed-drug combination tablet and higher pill 
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counts are involved, which may infl  uence adherence 
and complicate drug logistics; 3) EFV is consider-
ably more expensive; 4) EFV cannot be used in chil-
dren aged <3 years; and 5) a number of studies have 
shown that although plasma NVP levels are reduced 
by RMP, they still remain within the effective range 
and there is thus no signifi  cant effect on the clinical 
or virological impact of the drug.7–12
Expert opinion is still divided on the clinical and 
virological effi  cacy of NVP with RMP in TB patients. 
There is also concern that the use of NVP under pro-
gramme conditions might be associated with a rela-
tively higher risk of hepatotoxicity. 
Published information on these issues from pro-
gramme settings in sub-Saharan Africa is limited. 
Among HIV-infected patients with TB who received 
concurrent NVP- and RMP-based treatment under 
routine programme conditions, we thus report on 
1) clinical, immunological and virological outcomes 
and 2) safety—the incidence of hepatotoxicity and 
other reported side effects. 
METHODS 
Design
Retrospective cohort study using routine programme 
data.
Study setting and population
This study was conducted in Thyolo District, one of 
the largest rural districts in southern Malawi with 
about 587 000 inhabitants.13 The district has one main 
public hospital and 29 health centres. This study in-
cluded all ART-naïve adult HIV-infected new TB pa-
tients registered at Thyolo District hospital between 
June and December 2007 who received TB treatment 
along with NVP-based ART.
Management of the TB-HIV co-infected patient
TB patients are diagnosed, registered and treated 
according to national3,4 and WHO14 guidelines. TB 
treatment for new patients includes a 2-month initial 
phase of RMP, isoniazid (INH) and pyrazinamide 
(PZA), with additional ethambutol for sputum smear-
positive patients, followed by a 4-month continua-
tion phase of INH and RMP.
Newly diagnosed TB patients receive HIV testing and 
counselling. Those who are HIV-positive are offered 
cotrimoxazole prophylaxis if there are no contra-
indications. The timing of ART initiation is based 
on the degree of immune-defi   ciency: patients with 
CD4 count < 200 cells/mm3 start ART as soon as 
they are stabilised on TB treatment (usually between 
2 and 8 weeks); patients with a CD4 count of 200–
350 cells/mm3 start ART on completion of the inten-
sive phase of anti-tuberculosis treatment (usually after 
8 weeks); and those with CD4 counts > 350 cells/mm3 
start ART after completion of anti-tuberculosis treat-
ment. First-line ART in Malawi consists of a fi  xed-dose 
combination of d4T+3TC+NVP, using zidovudine 
(AZT) and efavirenz (EFV) as alternatives in cases of 
d4T and NVP-related side-effects.3 Once started on 
ART, patients are reviewed 2 weeks later and then 
once monthly, provided there are no complications 
or drug side-effects. Pyridoxine prophylaxis is sys-
tematically offered to reduce the incidence of periph-
eral neuropathy. TB treatment and ART are offered 
free of charge in Thyolo. 
Clinical, immunological and virological outcomes 
TB treatment outcomes were defi  ned as cured if a spu-
tum smear-positive patient became smear-negative on 
completion of TB treatment; completed treatment if a 
patient completed the full course of TB treatment 
without sputum confi  rmation; dead if a patient died 
for any reason while on treatment; lost to follow-up 
if a patient did not attend the clinic for ⩾2 months 
after the scheduled follow-up appointment; stopped 
treatment if a patient was known to have stopped 
treatment for any reason during treatment; or trans-
ferred out if a patient had transferred out perma-
nently to another treatment facility. As Thyolo has a 
well developed network of community volunteers 
and nurses who follow patients up at home, reliable 
ascertainment of deaths is possible.15
Weight and CD4 count (measured using the Partec 
Cyfl  ow Counter, Partec GmbH, Münster, Germany) 
were measured at baseline and at the end of TB treat-
ment. Viral load (measured using the Roche Ampli-
cor polymerase chain reaction technique [Roche, 
Grenzach-Whylen, Germany]) was measured at the 
end of TB treatment (viral load <50 copies/ml = 
u  ndetectable threshold), with all patients complet-
ing treatment requested to return to Thyolo hospital 
for this. The theoretical cut-off time for determin-
ing virological failure was set to be the end of anti-
t  uberculosis treatment, and thus 6 months or 24 weeks 
from the date of starting anti-tuberculosis treatment. 
Hepatotoxicity and other side effects 
Alanine transferase (ALT) levels were measured at 
baseline, at 1, 2 and 3 months and at the end of TB 
treatment to measure hepatotoxicity events, which 
were classifi  ed by grade according to the AIDS Clinical 
Trials Group (ACTG)3 as follows: Grade 0 (<1.25 × 
upper limit of normal [ULN < 40 U/ml]), Grade 1 
(1.25–2.5 × ULN), Grade 2 (2.6–5 × ULN), Grade 3 
(5.1–10 × ULN), Grade 4 (>10 × ULN). Hepato-
toxicity was defi  ned as ALT elevations ⩾ Grade 2. Pa-
tients were monitored clinically for other side effects 
and these were reported in the patient fi  le. Peripheral 
neuropathy was diagnosed if the patient complained 
of pain, paraesthesiae, numbness or weakness of the 
lower limbs.3
Data collection and statistical analysis
Structured forms were used to gather patient informa-
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software (Fuchia, Epicentre, Paris, France). A χ2 test 
was used to examine differences between propor-
tions; the level of signifi  cance was set at P ⩽ 0.05 and 
95% confi  dence intervals (CIs) were used through-
out. Data were analysed using STATA/IC 10.0 soft-
ware (Stata Corporation, College Station, TX, USA). 
Ethical approval
General measures are provided in the Thyolo District 
ART facilities to ensure patient confi  dentiality, con-
sent for HIV testing, and counselling and support for 
those who receive a positive HIV test result. The data 
in this study did not include patient identifi  ers. The 
Malawi National Health Science Research Commit-
tee provides general oversight and approval for the 
collection and use of routine programmatic data for 
monitoring and evaluation, and does not require a 
formal submission for ethical approval for the type 
of study conducted in this paper, as the procedures 
were in line with the recommended national proto-
col.3 This study was nevertheless submitted to and re-
ceived ethical approval from the independent ethical 
review board of Médecins sans Frontières, Belgium, 
and the Ethics Advisory Group of the Inter  national 
Union Against Tuberculosis and Lung Disease, Paris. 
RESULTS
Characteristics of the study population 
A total of 170 HIV-infected TB patients started ART 
after being diagnosed with TB during the study period. 
Of these, 14 had missing data for TB outcome or date 
of outcome and were excluded from the analysis. 
Table 1 shows the baseline socio-demographic char-
acteristics as well as nutritional status, TB type, base-
line CD4 and ALT levels of the 156 patients included 
in the study. Malnutrition was assessed using body 
mass index (BMI), defi  ned as weight in kg divided by 
height in m2. An adult with a BMI of <18.5 kg/m2 
was considered to be malnourished; this was the case 
in 48% of adult TB patients. All patients were started 
on an ART regimen of d4T+3TC+NVP. Patients 
with CD4 count < 200 cells/mm3 initiated ART after a 
median of 14 (interquartile range [IQR] 13–15) days 
from the time of starting TB treatment and patients 
with CD4 ⩾ 200–350 cells/mm3 after a median of 
55 days (IQR 54–56), in accordance with clinical 
guidelines. Patients were on concurrent TB treatment 
and ART for a median of 5 months (IQR 3.8–5.5). 
Clinical, immunological and virological outcomes 
Table 2 shows standardised TB outcomes for patients 
on concurrent TB treatment and ART. The treatment 
success rate was 87%, while 10% of patients died dur-
ing the course of anti-tuberculosis treatment. Patient 
deaths occurred a median of 1.7 months (IQR 0.5–
3.1) after starting TB treatment. A higher proportion of 
older patients (⩾40 years) died than younger patients 
(<40 years), (17% vs. 7%, P = 0.05), and a higher 
proportion of patients with CD4 < 200 cells/mm3 
died than those with CD4 ⩾ 200 cells/mm3 (100% vs. 
0%, P = 0.02, data not shown).
Table 3 shows weight gain, immunological recov-
ery and end of treatment viral loads for those patients 
who completed TB treatment successfully. The mean 
increase in body weight among adults was 4.4 kg 
(95%CI 3.3–5.5) and among children, 1.7 kg (95% CI 
6.6–9.9). Mean increase in CD4 count from baseline 
Table 1 Baseline  socio-demographic  characteristics, 
nutritional status, TB type, baseline CD4 and ALT levels 
of HIV-infected TB patients receiving concurrent TB treatment 
and ART, Thyolo, Malawi
Variable n (%)
Total 156
Sex 
 Females
 Males 
 71  (45.5)
 85  (54.5) 
Age, years
  <15 
 15–29
 30–39
  ⩾40 
 Median  [IQR]
  6  (3.9)
 34  (21.8)
  63 (40.4 )
 53  (34.0)
 35  [29–42]
TB type
 Smear-positive  PTB
 Smear-negative  PTB
 EPTB
 66  (42.3)
 65  (41.7)
 25  (16.0)
CD4 cell count, cells/mm3
 Adults  (n = 150)
  <50
  50–199
  200–349
  ⩾350
  Median  [IQR]
 Children  (n = 6)*
  Median  [IQR] 
 38  (25.3)
 79  (52.7)
 30  (20.0)
  3  (2.0)
113 [47–186]
520 [212–732]
BMI, kg/m2†
  <16.0
 16–18.49
  ⩾18.5
 Median  [IQR] 
 20  (13.4)
 53  (35.5)
 76  (51.0)
 18.5  [16.7–20.4]
Baseline ALT levels‡
 Grade  0
 Grade  1
 Grade  2
 Grade  3
 Grade  4
148 (97.4)
  2  (1.3)
  1  (0.7)
  0
  1  (0.7)
* 1 unknown record. 
† 7 unknown records.
‡ 4 unknown records.
TB  = tuberculosis; ALT = alanine transferase; HIV = human immuno-
deﬁ  ciency virus; ART = antiretroviral treatment; IQR = interquartile range; 
PTB = pulmonary TB; EPTB = extra-pulmonary TB; BMI = body mass index.
Table 2  TB treatment outcomes for patients on concurrent 
TB treatment and ART, Thyolo, Malawi (N = 156)
TB treatment outcome n (%)
Treatment success*
Died
Lost to follow-up
Transferred out
136 (87.1)
 16  (10.3)
  0
  4  (2.6)
* Includes patients who were cured (sputum conﬁ  rmed negative) and pa-
tients who completed tuberculosis treatment. 
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was 140 cells/mm3 (95% CI 117–162 cells/mm3). Of 
the 136 patients treated successfully, 76 (56%) had 
viral load measured at the end of treatment 
and of these, 56 (74%) had an undetectable viral 
load (<50 copies/ml); 17 had a viral load of 50–
999 copies/ml and three patients had viral loads > 
1000 copies/ml. These three patients had been on 
ART for only between 5.5 and 5.7 months. 
Hepatotoxicity and other reported drug side effects
At baseline, two (1.3%) patients had signifi  cantly ele-
vated ALT levels (Grade 2 and above). This included 
one patient with a Grade 2 ALT elevation and one 
with a Grade 3 elevation. ART was deferred in the 
latter for 6 weeks, when ALT levels had dropped to 
normal. The patient was started on NVP-based ART 
and did not have any further ALT elevations. Two 
(1.3%) patients developed Grade 2 and one (0.6%) 
Grade 3 ALT elevations at 1 and 2 months after 
starting TB treatment (incidence rate per 10 years of 
follow-up 4.2, 95%CI 1.4–13.1). 
The Figure shows mean ALT levels among patients 
during the period of TB treatment. The incidence of 
other drug-related side effects was very low: 8 (5%) 
patients presented with Grade 1 peripheral neuropa-
thy (PN), 2 (1.3%) with Grade 2 PN, and 1 (0.6%) 
with Grade 1 rash. All the reported side effects 
o  ccurred among patients with baseline CD4 count < 
200 cells/mm3. There were no deaths in patients who 
reported side effects. 
DISCUSSION 
This study showed that among HIV-infected TB pa-
tients receiving RMP-based TB treatment and NVP-
based ART concurrently, 87% completed TB treat-
ment successfully, with good gains in body weight 
and CD4 count (immunological recovery). Concur-
rent treatment using NVP and RMP also appears safe 
under programme conditions, with a low incidence 
of signifi  cant ALT elevations and other reported drug 
side effects. 
Of TB patients who had viral load measured at the 
end of TB treatment, 76% had undetectable levels of 
HIV-1 virus, and this fi  nding compares well with pa-
tients on ART (without concurrent RMP) in both in-
dustrialised16 and other resource-limited countries.17 
However, recent data from South Africa suggest that 
patients receiving concurrent RMP and NVP-based 
ART had a higher risk of virological failure in the 
fi  rst 18 months of treatment compared to patients re-
ceiving only NVP-based ART.18 It would thus be nec-
essary to be cautious and follow these patients and 
report on their virological outcomes over a longer pe-
riod. Our conclusions on viral loads are also limited 
by the fact that a considerable proportion of patients 
(42%) on decentralised follow-up at distant health 
facilities did not return to the Thyolo Hospital for 
blood collection. This is attributable to issues of dis-
tance and transport costs, where public transport 
networks are relatively expensive and poorly devel-
oped.2,19 Our viral load data thus need to be inter-
preted with caution: there might be data bias, as we 
do not really know what proportion of missing viral 
load data could be equated to failure. This practical 
shortcoming highlights the urgent need for access to 
an easy to use point-of-care viral load test for rural 
areas such as Thyolo. 
Furthermore, if we assume that viral loads of 
less than 1000 copies/ml might be related to ‘blips’ 
—a transient viraemia that returns spontaneously 
to undetectable levels without apparent clinical 
c  onsequences20—there were three (4%) patients with 
viral load titres ⩾1000 copies/ml who did not mani-
fest any clinical or immunological signs. We do not 
Table 3  Weight gain, immunological recovery and viral loads 
at the end of TB treatment (n = 136)
Outcome
Body weight, kg, mean increase (95%CI) 
 Adults  (n = 108/131)
 Children  (n = 2/6)
CD4 count, cells /mm3, mean increase (95%CI) 
 Adults  (n = 83/131)
 Children  (n = 0/6)
Viral load at the end of treatment, n (%)
 Adults  (n = 76/131) 
  Undetectable  (<50 copies  /ml)
  50–999  copies  /ml
  1000–9999  copies  /ml
  ⩾10 000 copies /ml
 Children  (n = 0/6)
  4.4  (3.3–5.4)
  1.7  (−6.6–9.9)
140 (117–162)
 —
 56  (73.7)
 17  (22.4)
  1  (1.3)
  2  (2.6)
 —
TB = tuberculosis; CI = conﬁ  dence interval.
Figure  Mean ALT levels over time for patients on concurrent 
rifampicin and nevirapine treatment, Thyolo, Malawi. * ALT 
unknown for four patients. ALT = alanine transferase; TB = 
tuberculosis; CI = conﬁ  dence interval.Concomitant   NVP-   and   RMP-based   treatment  201
know the reasons for this, but it could be related to 
high baseline viral load titres, insuffi   cient time on 
ART, poor adherence, primary resistance or poor 
clinical reporting. Although this may not seem high 
at a programme level, on a national scale in Malawi 
the implications could be considerable. For example, 
with about 25  000 newly registered TB cases each 
year in Malawi (77% HIV prevalence), about 18 865 
(98%) co-infected patients would be eligible for com-
bined NVP and RMP treatment, of whom 755 might 
have virological failure that could be missed without 
a viral load test. The poor correlation of clinical, pill 
count monitoring, immunological and other existing 
forms of adherence monitoring with inadequate viral 
suppression has been shown in a study conducted in 
Blantyre, Malawi.21 These short-comings again high-
light the urgent need for access to an easy to use 
point-of-care viral load test. 
The incidence of side effects with concomitant 
NVP and RMP treatment, particularly hepatotoxicity, 
is of critical importance in resource-limited district set-
tings where laboratory facilities are limited. The data 
from this study are thus reassuring in that both base-
line and ‘on treatment’ incidence of ALT ele  vations 
were very low and did not complicate patient manage-
ment or safety. The fi  ndings are also consistent with 
fi  ndings from Spain22 and recent operational data from 
Botswana, which showed excellent virological, im-
munological responses and safety among HIV-infected 
TB patients who received concomitant NVP-based 
ART and RMP-based TB treatment.12 We also had a 
relatively low incidence of peripheral neuropathy. 
An encouraging fi  nding of this analysis is the rel-
atively low TB case fatality rate of 10%, which is 
considerably lower than previously reported from 
Malawi.2,23 This might be linked to the fact that 
75% of the cohort with CD4 counts < 200 cells/mm3 
were started on ART within a median of 2 weeks, 
and this early initiation of ART might be infl  uencing 
survival.21
The strengths of this study were that 1) outcomes 
were reliably ascertained using registers that are ro-
bust and regularly checked by supervision teams, 
deaths were reliably ascertained, and there were no 
patients lost to follow-up, and the zero loss to follow-
up refl  ects the good interaction between health services 
and the community, with information about deaths 
being reliably ascertained and good tracing of late at-
tendees;15 and 2) the data come from a programme 
setting and therefore probably refl  ect the operational 
reality on the ground. 
The limitations of the study are that 1) patients 
were followed up only until the end of TB treatment 
and we are thus unable to report on longer term viro-
logical outcomes; and 2) data were missing in terms 
of laboratory parameters, and in particularly viral 
loads, due to the fact that many patients did not re-
turn to the hospital for blood collection for viral load 
at the end of TB treatment. 
Under programme conditions in a rural district in 
Malawi, concomitant NVP and RMP treatment is as-
sociated with good TB treatment outcomes and ap-
pears safe. Further follow-up of patients who complete 
TB treatment successfully would be useful to ascertain 
the longer term effects of this concurrent treatment. 
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RÉSUMÉ
CONTEXTE :    Hôpital de district de Thyolo, Malawi 
rural.
OBJECTIFS :    Décrire 1) les ressources cliniques, immu-
nologiques et virologiques ; et 2) le degré de sécurité 
chez les patients infectés par le virus de l’immunodéfi  -
cience humaine (VIH) et atteints de tuberculose (TB) 
ayant subi un traitement basé simultanément sur la névi-
rapine (NVP) et la rifampicine (RMP). 
SCHÉMA :  Etude rétrospective de cohorte.
MÉTHODES :    Analyse des données du programme de 
juin à décembre 2007.
RÉSULTATS :    Sur un total de 156 tuberculeux infectés 
par le VIH ayant débuté un traitement antirétroviral 
basé sur la NVP, 136 (87%) ont achevé leur traitement 
antituberculeux avec succès, 16 (10%) sont décédés et 5 
(4%) ont été transférés ailleurs. L’augmentation moyenne 
du poids corporel a été de 4,4 kg (IC95% 3,3–5,4) et 
celle des CD4 de 140 cellules/mm3 (IC95% 117–162). 
Parmi les patients ayant achevé leur traitement TB et 
chez qui on a mesuré la charge virale, les niveaux de 
celle-ci étaient indétectables (<50 copies/ml) chez 74 
(74%), alors qu’elle était de 50–1000 copies/ml chez 
17 (22%). Une hépatotoxicité était présente chez deux 
(1,3%) patients au début. Des augmentations de l’enzyme 
alanine transaminase sont survenues au cours du traite-
ment TB chez deux patients de degré 2 et chez un pa-
tient de degré 3 (taux d’incidence pour 10 ans de suivi = 
4,2 ; IC95% 1,4–13,1). Aucun décès n’a été signalé par 
hépatotoxicité.
CONCLUSIONS :    Dans un district rural du Malawi, le 
traitement concomitant par NVP et RMP va de pair 
avec de bons résultats du traitement TB et semble dé-
pourvu de risque. Il serait utile de suivre plus longtemps 
les patients pour s’assurer des effets à plus long terme de 
ce traitement simultané.
RESUMEN
MARCO DE REFERENCIA:  El hospital distrital de Thyolo 
en una zona rural de Malawi. 
OBJETIVOS:    Comunicar el desenlace desde el punto de 
vista clínico, inmunológico y virológico y la seguridad 
toxicológica del tratamiento, en pacientes con tubercu-
losis (TB), coinfectados por el virus de la inmunodefi  -
ciencia humana (VIH), que recibieron simultáneamente 
tratamientos a base de nevapirina (NVP) y rifampicina 
(RMP). 
DISEÑO:  Fue este un estudio retrospectivo de cohortes.
MÉTODOS:    Se analizaron los datos del programa entre 
junio y diciembre del 2007. 
RESULTADOS:    De los 156 pacientes infectados por el 
VIH y con TB que comenzaron tratamiento antirretro-
vírico basado en NVP, 136 (87%) completaron con éxito 
el tratamiento antituberculoso, 16 (10%) fallecieron y 5 
(4%) se transfi  rieron a otros centros. La media del au-
mento de peso corporal en los adultos fue 4,4 kg (IC95% 
3,3–5,4) y del recuento de CD4 fue 140 células/mm3 
(IC95% 117–162). Se midió la viremia en 76 pacientes 
que completaron el tratamiento antituberculoso: en 
74% la viremia no alcanzó el umbral de detección (menos 
de 50 copias/ml) y en 17 (22%) se encontraron e  ntre 50 y 
1000 copias/ml. Antes de comenzar la pauta antituber-
culosa se observaron signos de hepatotoxicidad en dos 
pacientes (1,3%) y durante el tratamiento dos pacientes 
presentaron un aumento de la alanina-aminotransferasa 
de grado 2 y un paciente un aumento de grado 3 (tasa 
de incidencia en 10 años de seguimiento 4,2; IC95% 
1,4–13,1). No se comunicaron defunciones asociadas 
con la hepatotoxicidad. 
CONCLUSIÓN:    En un distrito rural de Malawi, los tra-
tamientos combinados a base de NVP y RMP ofrecieron 
desenlaces terapéuticos favorables con una buena seguri-
dad toxicológica. Un mayor seguimiento de los pacien-
tes podría ser útil a fi  n de verifi  car los efectos a largo 
plazo de estos tratamientos simultáneos.